VA HB570 | 2024 | Regular Session

Status

Spectrum: Partisan Bill (Democrat 27-0)
Status: Vetoed on April 8 2024 - 100% progression
Action: 2024-04-17 - House sustained Governor's veto
Text: Latest bill text (Enrolled) [HTML]

Summary

Prescription Drug Affordability Board established; drug cost affordability review. Establishes the Prescription Drug Affordability Board for the purpose of protecting the citizens of the Commonwealth and other stakeholders within the health care system from the high costs of prescription drug products. The bill requires the Board to meet in open session at least four times annually, with certain exceptions and requirements enumerated in the bill. Members of the Board are required to disclose any conflicts of interest, as described in the bill. The bill also creates a stakeholder council for the purpose of assisting the Board in making decisions related to drug cost affordability. The bill tasks the Board with identifying prescription, generic, and other drugs, as defined in the bill, that are offered for sale in the Commonwealth and, at the Board's discretion, conducting an affordability review of any prescription drug product. The bill lists factors for the Board to consider that indicate an affordability challenge for the health care system in the Commonwealth or high out-of-pocket costs for patients. The bill also provides that any person aggrieved by a decision of the Board may request an appeal of the Board's decision and that the Attorney General has authority to enforce the provisions of the bill. The bill provides that the Board shall establish no more than 12 upper payment limit amounts annually between January 1, 2025, and January 1, 2028. Prescription Drug Affordability Board established; drug cost affordability review. Establishes the Prescription Drug Affordability Board for the purpose of protecting the citizens of the Commonwealth and other stakeholders within the health care system from the high costs of prescription drug products. The bill requires the Board to meet in open session at least four times annually, with certain exceptions and requirements enumerated in the bill. Members of the Board are required to disclose any conflicts of interest, as described in the bill. The bill also creates a stakeholder council for the purpose of assisting the Board in making decisions related to drug cost affordability. The bill tasks the Board with identifying prescription, generic, and other drugs, as defined in the bill, that are offered for sale in the Commonwealth and, at the Board's discretion, conducting an affordability review of any prescription drug product. The bill lists factors for the Board to consider that indicate an affordability challenge for the health care system in the Commonwealth or high out-of-pocket costs for patients. The bill also provides that any person aggrieved by a decision of the Board may request an appeal of the Board's decision and that the Attorney General has authority to enforce the provisions of the bill. The bill provides that the Board shall establish no more than 12 upper payment limit amounts annually between January 1, 2025, and January 1, 2028. The bill requires the Board to report its findings and recommendations to the General Assembly twice annually, beginning on July 1, 2025, and December 31, 2025. Provisions of the bill shall apply to state-sponsored and state-regulated health plans and health programs and obligate such policies to limit drug payment amounts and reimbursements to an upper payment limit amount set by the Board, if applicable, following an affordability review. The bill specifies that Medicare Part D plans shall not be bound by such decisions of the Board. The bill also requires the nonprofit organization contracted by the Department of Health to provide prescription drug price transparency to provide the Board access to certain data reported by manufacturers. The bill has a delayed effective date of January 1, 2025, and is identical to

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Prescription Drug Affordability Board; established, drug cost affordability review, report.

Sponsors


Roll Calls

2024-03-05 - Senate - Senate: Passed Senate (25-Y 15-N) (Y: 25 N: 15 NV: 0 Abs: 0) [PASS]
2024-03-04 - Senate - Senate: Constitutional reading dispensed (40-Y 0-N) (Y: 40 N: 0 NV: 0 Abs: 0) [PASS]
2024-02-29 - Senate - Senate: Reported from Finance and Appropriations (10-Y 4-N) (Y: 10 N: 4 NV: 0 Abs: 0) [PASS]
2024-02-26 - Senate - Senate: Reported from Commerce and Labor (10-Y 5-N) (Y: 10 N: 5 NV: 0 Abs: 0) [PASS]
2024-02-22 - Senate - Senate: Rereferred from Education and Health (12-Y 0-N) (Y: 12 N: 0 NV: 0 Abs: 0) [PASS]
2024-02-13 - House - House: VOTE: Passage (52-Y 46-N) (Y: 52 N: 46 NV: 0 Abs: 2) [PASS]
2024-02-09 - House - House: Reported from Appropriations (11-Y 9-N) (Y: 11 N: 9 NV: 0 Abs: 2) [PASS]
2024-02-07 - House - House: Subcommittee recommends reporting (5-Y 2-N) (Y: 5 N: 2 NV: 0 Abs: 2) [PASS]
2024-02-01 - House - House: Reported from Labor and Commerce with substitute (12-Y 10-N) (Y: 12 N: 10 NV: 0 Abs: 0) [PASS]

History

DateChamberAction
2024-04-17HouseHouse sustained Governor's veto
2024-04-08 Governor: Vetoed by Governor
2024-03-27 Governor: Governor's Action Deadline 11:59 p.m., April 8, 2024
2024-03-27HouseEnrolled Bill communicated to Governor on March 27, 2024
2024-03-26HouseSigned by Speaker
2024-03-25SenateSigned by President
2024-03-25HouseBill text as passed House and Senate (HB570ER)
2024-03-25HouseEnrolled
2024-03-05SenatePassed Senate (25-Y 15-N)
2024-03-05SenateRead third time
2024-03-04SenateConstitutional reading dispensed (40-Y 0-N)
2024-02-29SenateReported from Finance and Appropriations (10-Y 4-N)
2024-02-26SenateRereferred to Finance and Appropriations
2024-02-26SenateReported from Commerce and Labor (10-Y 5-N)
2024-02-22SenateRereferred to Commerce and Labor
2024-02-22SenateRereferred from Education and Health (12-Y 0-N)
2024-02-14SenateReferred to Committee on Education and Health
2024-02-14SenateConstitutional reading dispensed
2024-02-13HouseVOTE: Passage (52-Y 46-N)
2024-02-13HouseRead third time and passed House (52-Y 46-N)
2024-02-12HouseEngrossed by House - committee substitute HB570H1
2024-02-12HouseCommittee substitute agreed to 24106760D-H1
2024-02-12HouseRead second time
2024-02-11HouseRead first time
2024-02-09HouseReported from Appropriations (11-Y 9-N)
2024-02-07HouseSubcommittee recommends reporting (5-Y 2-N)
2024-02-01HouseAssigned App. sub: Health & Human Resources
2024-02-01HouseReferred to Committee on Appropriations
2024-02-01HouseCommittee substitute printed 24106760D-H1
2024-02-01HouseReported from Labor and Commerce with substitute (12-Y 10-N)
2024-01-30HouseAssigned L & C sub: Subcommittee #1
2024-01-25HouseReferred to Committee on Labor and Commerce
2024-01-25HouseReferred from Health and Human Services by voice vote
2024-01-09HouseReferred to Committee on Health and Human Services
2024-01-09HousePrefiled and ordered printed; offered 01/10/24 24100122D

Same As/Similar To

SB274 (Similar To) 2024-04-17 - Senate sustained Governor's veto

Subjects


Code Citations

ChapterArticleSectionCitation TypeStatute Text
321276.12(n/a)See Bill Text
321276.19(n/a)See Bill Text
5413442.02(n/a)See Bill Text

Virginia State Sources

TypeSource
Summaryhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+sum+HB570
Texthttps://lis.virginia.gov/cgi-bin/legp604.exe?241+ful+HB570+hil
Texthttps://lis.virginia.gov/cgi-bin/legp604.exe?241+ful+HB570H1+hil
Texthttps://lis.virginia.gov/cgi-bin/legp604.exe?241+ful+HB570ER+hil
Amendmenthttps://committees.lis.virginia.gov/pdfs/drafts/24106760D.pdf
Amendmenthttps://lis.virginia.gov/cgi-bin/legp604.exe?241+amd+HB570AG
Supplementhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+oth+HB570F122+PDF
Supplementhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+oth+HB570FH1122+PDF
Supplementhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+oth+HB570FER122+PDF
Roll Callhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+vot+H14V0080+HB0570
Roll Callhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+vot+H0205V0023+HB0570
Roll Callhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+vot+H02V0150+HB0570
Roll Callhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+vot+HV0653+HB0570
Roll Callhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+vot+S04V0184+HB0570
Roll Callhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+vot+S02V0107+HB0570
Roll Callhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+vot+S05V0509+HB0570
Roll Callhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+vot+SV0926HB0570+HB0570
Roll Callhttps://lis.virginia.gov/cgi-bin/legp604.exe?241+vot+SV0999HB0570+HB0570

Bill Comments

feedback